692 related articles for article (PubMed ID: 25743035)
21. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
22. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
[TBL] [Abstract][Full Text] [Related]
23. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
[TBL] [Abstract][Full Text] [Related]
24. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Breslin TM; Cohen L; Sahin A; Fleming JB; Kuerer HM; Newman LA; Delpassand ES; House R; Ames FC; Feig BW; Ross MI; Singletary SE; Buzdar AU; Hortobagyi GN; Hunt KK
J Clin Oncol; 2000 Oct; 18(20):3480-6. PubMed ID: 11032588
[TBL] [Abstract][Full Text] [Related]
25. Role of sentinel lymphadenectomy combined with intraoperative ultrasound in the assessment of locally advanced breast cancer after neoadjuvant chemotherapy.
Yu JC; Hsu GC; Hsieh CB; Yu CP; Chao TY
Ann Surg Oncol; 2007 Jan; 14(1):174-80. PubMed ID: 17066228
[TBL] [Abstract][Full Text] [Related]
26. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
27. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer.
Patel NA; Piper G; Patel JA; Malay MB; Julian TB
Am Surg; 2004 Aug; 70(8):696-9; discussion 699-700. PubMed ID: 15328803
[TBL] [Abstract][Full Text] [Related]
28. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
[TBL] [Abstract][Full Text] [Related]
29. [The feasibility and the role of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
Péley G; Török K; Farkas E; Mátrai Z; Horváth Z; Sinkovics I; Hitre E; Rényi-Vámos F; Orosz Z; Köves I
Magy Onkol; 2006; 50(1):19-23. PubMed ID: 16617379
[TBL] [Abstract][Full Text] [Related]
30. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.
Newman EA; Sabel MS; Nees AV; Schott A; Diehl KM; Cimmino VM; Chang AE; Kleer C; Hayes DF; Newman LA
Ann Surg Oncol; 2007 Oct; 14(10):2946-52. PubMed ID: 17514407
[TBL] [Abstract][Full Text] [Related]
31. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine needle aspiration.
Yu Y; Cui N; Li HY; Wu YM; Xu L; Fang M; Sheng Y
BMC Cancer; 2016 Oct; 16(1):808. PubMed ID: 27756234
[TBL] [Abstract][Full Text] [Related]
32. [Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
Mátrai Z; Tóth L; Polgár C; Láng I; Gõdény M; Sinkovics I; Horváth Z; Bidlek M; Udvarhelyi N; Bartal A; Sávolt A; Ujhelyi M; Kásler M
Magy Onkol; 2011 Jun; 55(2):73-84. PubMed ID: 21655472
[TBL] [Abstract][Full Text] [Related]
33. Selective sentinel lymph node biopsy in male breast cancer.
Martin-Marcuartu JJ; Alvarez-Perez RM; Sousa Vaquero JM; Jimenez-Hoyuela García JM
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(3):146-150. PubMed ID: 29246402
[TBL] [Abstract][Full Text] [Related]
34. [Sentinel lymphatic node biopsy for breast cancer in practice].
Strnad P; Rob L; Krízová H; Zuntová A; Chod J; Halaska M
Ceska Gynekol; 2005 Jul; 70(4):291-5. PubMed ID: 16128130
[TBL] [Abstract][Full Text] [Related]
35. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
[TBL] [Abstract][Full Text] [Related]
36. Complete axillary conversion after neoadjuvant chemotherapy in locally advanced breast cancer: a step towards conserving axilla?
Arimappamagan A; Kadambari D; Srinivasan K; Krishnan R; Elangovan S; Reddy KS
Indian J Cancer; 2004; 41(1):13-7. PubMed ID: 15105574
[TBL] [Abstract][Full Text] [Related]
37. The problem of axillary staging in breast cancer after neoadjuvant chemotherapy. Role of targeted axillary dissection and types of lymph node markers.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Aguayo-Albasini JL
Cir Esp (Engl Ed); 2020 Nov; 98(9):510-515. PubMed ID: 32386728
[TBL] [Abstract][Full Text] [Related]
38. Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study.
Aksoy SO; Sevinc Aİ; Ünal M; Balci P; Görkem İB; Durak MG; Ozer O; Bekiş R; Emir B
Medicine (Baltimore); 2020 Dec; 99(49):e23538. PubMed ID: 33285770
[TBL] [Abstract][Full Text] [Related]
39. Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.
Vriens BEPJ; Keymeulen KBMI; Kroep JR; Charehbili A; Peer PG; de Boer M; Aarts MJB; Heuts EM; Tjan-Heijnen VCG;
Oncotarget; 2017 Jul; 8(28):46557-46564. PubMed ID: 28177921
[TBL] [Abstract][Full Text] [Related]
40. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
